Bayer and Tempus Initiate Collaboration to Enable Precision Medicine by Broadening Access to Genomic Testing

Bayer
  • FLASCO
  • February 11, 2021

Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing a next-generation sequencing (NGS) based Tempus xT Solid Tumor assay at NO COST for a subset of metastatic colorectal cancer (mCRC) patients with microsatellite instability-high (MSI-H) and radioactive iodine refractory differentiated metastatic thyroid carcinoma (RAIR thyroid cancer). Healthcare professionals with eligible patients from the above tumor types can receive additional information at Tempus.com/bayerprogram and/or contacting Tempus at [email protected]. This program will only be offered for a limited time.

© 2020 FLASCO | Premium Website Design by The HDG

FLASCO